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1. Introduction 
Nitroxyl radicals (NRs), which are sometimes called "organic nitrogen oxides” exhibit a 
wide range of biological activities, e.g., hemodynamic effect, protection against ionizing 
radiation, suppression of oxidative stress in different types of pathology (Soule et al., 2007; 
Wilcox, 2010). Already in early studies of the simplest NRs, their antitumor activity was 
demonstrated on a model tumor, leukemia La (Konovalova et al., 1964) and their 
cytotoxicity was shown for HeLa cells (Klimek, 1966). Subsequent studies included: 1) in-
depth studies of antitumor activity of simple NRs (TEMPOL, TEMPO), 2) trials of 
therapeutical efficiency of NRs used in combination with the clinically approved anticancer 
drugs, and 3) synthesis and studies of hybrid compounds with NRs covalently bound to 
anticancer pharmacophores. Recent studies have shown that simple nitroxyls affect the cell 
viability through a redox-mediated signaling and induce a multifactor cell death response, 
including oxidative damage, cell cycle arrest and apoptosis (Gariboldi et al., 1998; 2000; 
2003; Suy et al., 2005). 
Nitroxide TEMPOL potentiates the cytotoxicity of doxorubicin in the culture of tumor cells 
with multidrug resistance (Gariboldi et al., 2006), and reduces its cardiotoxicity in rats 
(Monti et al, 1996). Combinations of low doses of nitroxyl TEMPO and doxorubicin or 
mitoxantrone exhibit additive or synergistic cytotoxicity, depending on the type of the 
tumor cells (Suy et al., 2005). In experiments on mice, nitroxyls at low doses (0.25–10 mg/kg) 
were shown to decrease toxicity of anticancer drugs substantially (Konovalova et al., 1991). 
A considerable amount of research has been carried out on hybrid compounds containing 
NRs linked covalently to an anticancer pharmacophore. Nitroxyl derivatives of 
(thio)phosphamides (Shapiro et al., 1971; Emanuel et al., 1976; Sosnovsky & Paul, 1984; 
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Sosnovsky & Li, 1985a), cyclophosphamide (Tsui et al., 1982), actinomycin D (Sinha et al., 
1979), ethylenimino triazines (Emanuel & Konovalova, 1992), nitrosoureas (Raikov et al., 
1985; Sosnovsky & Li, 1985b; Emanuel et al., 1986; Sen', 1993), 5-fluorouracil (Emanuel et al., 
1985; Sen' et al., 1989), daunorubicin (Emanuel et al., 1982) were synthesized and studied. In 
comparison with the parent compounds, nitroxyl derivatives of the cytostatic drugs possess 
lower overall toxicity in animal studies and higher values of the half inhibitory concentrations 
IC50 in cell cultures. At the same time, they exhibit higher chemotherapeutic indexes (are 
effective in a wider range of doses) and, in the cases studied, are characterized by fewer side 
effects. For example, ruboxyl, a nitroxyl derivative of daunorubicin, is 8-fold less toxic to 
mice than the parent compound. At optimal doses, ruboxyl is more effective in experimental 
animal tumors and has no cardiotoxicity (Emanuel et al., 1982, 1992). After a successful 
phase II clinical trials (1991), its further study was interrupted due to financial problems.  
Over the past 30 years, platinum complexes occupy leading positions among drugs for 
cancer chemotherapy. The antitumor activity of cisplatin (CP) was discovered in 1960s, and 
in 1978 it was approved for clinical use (Kelland, 2007). The subsequent search for improved 
cisplatin analogues resulted in introduction of carboplatin (1989) and oxaliplatin (2002) into 
clinical practice. About 15 other complexes, for various reasons, have been rejected in 
clinical trials. Currently, JM216 (satraplatin), picoplatin, and nanopolymer ProLindac, 
bearing the oxaliplatin moiety, are subject to clinical trials (Wheate et al., 2010) (Fig. 1). 
 
Figure 1. Platinum anticancer drugs which are in clinical use and undergoing clinical trials. 
Cisplatin and other bivalent platinum complexes are effective against a number of human 
tumors. They are used in almost half of the treatment regimes in combinations with other 
anticancer drugs (Wheate et al., 2010). Complexes of bivalent platinum are highly reactive 
and, therefore, they are highly toxic drugs. To avoid acute toxicity, cisplatin is administered 
by continuous infusion of a very dilute solution (Blokhin & Perevodchikova, 1984). Another 
disadvantage of cisplatin is a rapid development of tumor resistance to this drug (Koeberle 
et al., 2010). 
Complexes of Pt(IV), being chemically more inert than Pt(II) complexes, are characterized by 
moderate toxicity, and are suitable for oral administration. Complexes like satraplatin can 
pass through the digestive tract where they are absorbed into the bloodstream. With the 
bloodstream they reach organs and tissues, interact with cellular targets, and thus provide 
an antitumor effect (Kelland, 1999). Complexes of Pt(IV) are prodrugs (drug precursors) 
that, after entering into the cell or on the way to it, are reduced to corresponding active Pt(II) 
derivatives causing cytotoxic effect. At the same time, Pt(IV) complexes are potent inhibitors 
 
Platinum Complexes with Bioactive Nitroxyl Radicals: Synthesis and Antitumor Properties 387 
of proliferation of tumor cells including those resistant to cisplatin. Recent advances in the 
study of anticancer platinum amino complexes are summarized in a number of reviews 
(Kelland, 2007; Wheate et al., 2010; Klein & Hambley, 2009; Koeberle et al., 2010; Bonetti et 
al., 2009). 
This review focuses mainly on the authors’ data on synthesis and studies of new highly 
active platinum compounds with low toxicity, viz, Pt(II) and Pt(IV) complexes with 
biologically active aminonitroxyl radicals. In addition to biological activity, the advantage of 
such compounds is their paramagnetism which gives an opportunity to use them as spin 
labels in the study of the mechanism of antitumor action. The work involved the synthesis 
of platinum-nitroxyl complexes (PNCs), studies of their structure, physico-chemical 
properties and interactions with the main target, DNA. Studies of cytotoxic properties of 
PNCs, their impact on cell cycle and cell death were carried out using in vitro cultured 
tumor cells. Studies of antitumor activity, development of the tumor resistance, and 
synergistic antitumor effects of combinations of new complexes with cisplatin were 
performed in animal model tumor leukemia P388. 
2. Synthesis of PNCs 
2.1. Pt(II) complexes 
Most of platinum complexes with high antitumor activity are non-ionic compounds with the 
cis-arrangement of the amino ligands (Hambley, 1997) (Fig. 1). Synthesis of complexes with 
two identical amino ligands or one diamino ligand is similar to the synthesis of cisplatin and 
is generally outlined in Fig. 2. 
 
Figure 2. Synthesis of Pt(II) cis-diamino complexes. 
To achieve good yields, diiodo complexes cis-[Pt(RNH2)2I2] were prepared in the first step of 
the synthesis. The diiodo complexes were then converted to the target complexes by 
exchange reaction via water soluble dinitrato complexes (Fig. 2) (Dhara, 1970). 
Complexes with two bulky amino ligands, such as compounds 1 (see Fig. 4), poorly bind to 
the DNA target (Section 3). Presumably, this is the main cause of their weak antitumor 
activity. The search for the active complexes led to the development of synthesis of mixed-
ligand cis-diamino complexes containing only one bulky aminoligand (Giandomenico et al., 
1995). The key intermediate in this synthesis is the salt K[Pt(NH3)Cl3], which can be obtained 
in several ways (Oksanen & Leskela, 1994; Oksanen, 1997; Potucka et al., 2011). The 
described method (Giandomenico et al., 1995) was modified by us for the preparation of 
PNCs with general formulae 2 and 3 (Fig. 3, 4). 
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Figure 3. Synthesis of mixed amine complexes of platinum (II) (R – nitroxyl radical). 
 
Figure 4. Platinum(II) amino nitroxyl complexes. 
The formulae of complexes obtained are shown in Fig. 4 (Sen' et al., 1996, 1998, 2000). Two 
biradical complexes of type 1 were synthesized previously (Mathew et al., 1979; Claycamp 
et al., 1986). For the preparation of compounds of general formula 4, which are structural 
analogues of oxaliplatin, we synthesized the first nitroxyl with two vicinal amino groups, 
trans-3,4-diamino-2,2,6,6-tetramethylpiperidine-1-oxyl (Sen', 1989). Binuclear complex 5b 
was also obtained based on this radical. 
2.2. Pt(IV) complexes 
Complexes of Pt(IV) with mixed amino ligands can be obtained only by oxidation of the 
Pt(II) precursors. According to the published method (Giandomenico et al., 1995), the 
starting Pt(II) complexes 6 are oxidized with an excess of H2O2 under relatively harsh 
conditions (70 °C, ≥ 2 h). Under these conditions, the oxidation of Pt(II)-nitroxyl complexes 
leads to the formation of significant amount of by-products, probably as a result of 
oxidation of nitroxyl radical by Pt(IV) at elevated temperature. We found that catalytic 
amounts of salts of tungstic acid strongly accelerate the reaction so that preparative 
oxidation under mild conditions (0 – 20 °C) is limited only by the rate of dissolution of the 
starting complex and takes from 0.5 to 2.5 hours.  
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Figure 5. Synthesis of platinum(IV) complexes, R - nitroxyl radical, R '- carboxylic acid residue. 
This significantly increases the reaction selectivity and the yield of the target products. trans-
Dihydroxo complexes 7 resulted from the oxidation are of interest themselves. Their 
acylation with organic acid anhydrides leads to the trans-dicarboxylate derivatives 8 (Fig. 5) 
(Sen' et al., 2003, 2006). 
The method described allows one to introduce different amines and exchange the so-called 
leaving X-ligands at the step of preparation of Pt(II) complexes (Fig. 3) and incorporate 
various carboxylate ligands with the alkyl residue R' of different length at the final step (Fig. 
5). Thus, we can obtain the amino complexes of Pt(IV), which differ in chemical activity, 
solubility in water and aqueous-lipid distribution. The formulae of Pt(IV) complexes are 
shown in Fig. 6. 
 
Figure 6. Platinum(IV) amino nitroxyl complexes. 
The structure of PNCs was proved by elemental analysis and spectroscopic data (Sen' et al., 
1996, 1998, 2000, 2003, 2006). For complexes 2b, 4d, and 10a, the structures are determined 
by X-ray crystallography (Sen' et al., 2000, 2003; Chekhlov, 2005). 
3. Interaction of PNCs with DNA 
Reactivity of Pt(II) diamine complexes 4 depends strongly on the nature of leaving X-
ligands. Pseudo-monomolecular rate constants for X-ligands hydrolysis in complexes 4c, 4d, 
cisplatin, and 4e at 25 °C in 0.08 M NaOH are > 10–2, 1.2·10–4, 1.9·10–5, and 2.9·10–7 s–1, 
respectively, i.e., differ by five orders of magnitude (Shugalii et al., 1998). Therefore, the 
reaction of complexes with S- or N-donor groups can proceed either through the step of 
preliminary hydrolysis with the formation of an active intermediate aqua complex (Fig. 7, 
path A), or by the direct substitution of the X-ligands (path B). 
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Figure 7. Reaction of Pt(II) complexes with nucleophilic atom Nu of a target molecule. 
For relatively easily hydrolyzable complexes, including cisplatin, the reaction proceeds 
through the path A (Alderden et al., 2006), but for complexes of type 4e (X + X' = cyclobutane 
dicarboxylate) there is an evidence for direct substitution of the X-ligands by N-donor 
groups (Frey, 1993). 
It is known that cisplatin and its analogues bind mainly to the guanine and adenine bases of 
DNA with the formation of cross-links, thus perturbing the structure of DNA (Kelland, 
2007; Wheate et al., 2010). Analysis of the EPR spectra of DNA modified with PNCs, 
together with hydrolytic determination of platinated DNA bases, showed (Shugalii et al., 
1998) that complexes 30b and 4d form predominantly ( 95%) bidentate intrastrand adducts 
with DNA. In adducts formed by both complexes, the rotation of the nitroxyl radicals is 
equally slow (Fig. 8) (correlation time τ ~ 10–8 s–1). 
 
Figure 8. EPR spectra of free 4d in water (a) and ethanol (d), and DNA modified by 4d (b, e), and 30b (c, 
f) in aqueous 0.01 M NaHCO3 at Pt-to-nucleotide ratio r =0.16, 37C, 24 h. Spectra were recorded at 
magnetic modulation 0.32 mT, microwave power 5 (20C) and 0.5 mW (–196C), field scan 20 mT, scan 
time 8 min, time constant 1 s. 
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This result can be explained by immobilization of the radical moiety in the major DNA 
groove for the complex 30b adducts, and by the immobilization and/or by rigid structure of 
the double bound radical moiety in adducts formed by complex 4d. Adducts formed by 
complexes 31b and 32c whose radical moiety is separated from the Pt atom by the methylene or 
ethylene bridge, are characterized by an order of magnitude lower values of the parameter τ. 
Presumably, this phenomenon is related to partial release of nitroxyl moiety from relatively 
shallow major groove of DNA, which increases its rotational mobility (Sen’, 2002). 
Exciting opportunities for the instrumental use of PNCs were shown by Dunham et al., 
1998. An adduct of 30a complex with synthetic DNA fragment containing 11 base pairs was 
synthesized. Its structure in solution was determined by NMR based on the dependence 
between paramagnetic broadenings of protons of DNA bases and distances between bases 
and nitroxyl radical. Formation of the adduct was proved to result in the bending of DNA 
molecule that forms the angle ~80° with respect to the major groove, whereas the minor 
groove becomes strongly broaden. 
The ability of complexes 1 – 5 to bind to the isolated DNA in vitro was determined under 
standard conditions and characterized by a parameter r, which is equal to the number of 
linked labels per one nucleotide. In the series of complexes with the same amino ligand 4c—
e, parameter r grows with the increase in the rate of hydrolysis of X-ligands. Platinating 
activity of compounds with different amino ligands depends on the total volume of these 
ligands and/or their linear sizes. Bulky biradical complex 1c and complexes 31b and 32c, 
whose sizes are enlarged due to a methylene or ethylene bridge, bind to DNA 5 to 10 times 
less efficiently than cisplatin or complexes 4c, d (Fig. 9). 
 
Figure 9. Relationship between the platinating activity (r) and specific destabilization of the DNA 
duplex (Tm) for PNCs. The platination of DNA was carried out in 0.01 M NaHCO3 over a period of 24 h 
at 37 C at the initial molar ratio rin = 0.1. 
Ordinates in Fig. 9 are the values of specific destabilization of the DNA duplex, Tm, that 
corresponds to the decrease in the DNA melting temperature due to formation of one 
adduct per 100 nucleotides. These values were calculated according to the formula 
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Tm=(Tm′ – Tm)/100r, 
where Tm and Tm′ are the melting points for unmodified and platinated DNA, respectively. 
The data in Fig. 9 show that the low-activity complexes (with low r–values) cause the 
greatest disorder in the DNA duplex. Presumably, adducts of these complexes are readily 
recognized by the repair machinery. This is in agreement with the data on low antitumor 
activity of such complexes (see below). The binuclear complex 5b stabilizes DNA due to a 
predominant (~70%) formation of the interstrand crosslinks interfering with the thermal 
dissociation of the DNA duplex. It is interesting that bi- and trinuclear platinum amino 
complexes exhibit cytotoxic properties different from that of mononuclear ones, in 
particular, the former are active against cisplatin-resistant cells (Farrell et al., 1999). 
4. Cytotoxicity of PNCs in tumor cell cultures 
A simplified mechanism of cytotoxic effect of cisplatin and its analogs includes the transport 
of the complexes into the cell, their activation by the hydrolysis of leaving ligands (Cl—, 
carboxylates), penetration into the nucleus, and formation of adducts with DNA (Kelland, 
2007; Wheate et al., 2010). The DNA lesions are either repaired, or initiate a complex process 
of programmed cell death, i.e., apoptosis. In addition, it is known that cisplatin, directly or 
indirectly, causes the generation of reactive oxygen species. This process is important for the 
initiation of apoptosis (Miyajima et al., 1997; Bragado et al., 2007) and may also be 
responsible for side effects, e.g. nephrotoxicity (Tsutsumishita et al., 1998). 
Nitroxyl radicals are antioxidants, which can react with active radicals not only 
stoichiometrically, but also act as catalysts of redox reactions and mimetics of enzymatic 
systems. For example, in aqueous medium they perform superoxide dismutation through 
the reduction of radical HO2 by nitroxyl radical and the oxidation of radical O2─ by 
oxoammonium cation (Sen' et al., 1976, 2009; Goldstein et al., 2003) (Fig. 10). 
 
Figure 10. Superoxide dismutase-like activity of nitroxyl radicals 
Interestingly, the nitroxyl based catalysis of dismutation of HO2 radical, generated in 
organic compounds undergoing oxidation, is carried out by the pair of nitroxyl 
radical/hydroxylamine (Denisov, 1996) (Fig. 11) Thermodynamic data are presented in 
support of the latter mechanism in organic medium. The measured constants of forward 
and reverse reactions at 50 C are equal to 104 – 105 M–1·s–1 (Denisov, 1996). Existence of two 
mechanisms for different media is not excluded. It looks reasonable that in an aqueous  
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Figure 11. Catalytic disproportionation of radical HO2 in organic medium 
medium the preferred process is an electron transfer followed by a thermodynamically 
favorable hydration of oxoammonium cation (Fig. 10), while in an organic medium more 
typical reactions are the redox processes involving a hydrogen atom transfer (Fig. 11). 
Therefore, in biphasic aqueous-organic systems present in biological objects, both 
mechanisms are possible.  
Like other antioxidants, under certain conditions, nitroxyls may exhibit pro-oxidant activity. 
The structure and concentration of nitroxyls, the medium properties, and other hard-to- 
identify factors can determine their anti– or pro-oxidant effect. At submillimolar 
concentrations, nitroxyls, as a rule, exhibit antioxidant properties and protect cells from 
apoptosis (Wilcox, 2010). At millimolar concentrations, nitroxyls are cytotoxic toward 
cultured tumor cells (Gariboldi et al., 1998, 2000, 2003, 2006; Suy et al., 2005) and are active 
against model animal tumors (Konovalova et al., 1964; Suy et al., 2005). Nitroxyl radicals 
cause cell death both in the wild type and p53 mutant cells (Suy et al., 2005). The study of 
interplay of platinum and nitroxyl pharmacophores combined in one molecule is of interest 
also in connection with the recent discussions on application of antioxidants and redox-
active agents in tumor chemotherapy (Seifried, 2003; Wondrak, 2009). 
To elucidate the interaction between platinum and nitroxyl pharmacophores, we studied the 
effect of 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO) on the toxicity of 
cisplatin to HeLa cells. According to the published approach (Reynolds & Maurer, 2005; 
Chou, 2006), the dose-response relationships were determined for individual agents and 
their mixtures at a fixed concentrations ratio. These data were transformed into the 
combination index (CI) – dead cells fraction (fa) dependence (Fig. 12). In a wide range of 
fraction affected fa, values of log (CI) are positive, which indicates antagonism of the agents. 
In the range of relatively high fraction affected, corresponding to millimolar concentrations 
of 4-amino-TEMPO, a transition to negative values of log (CI) takes place which means the 
mutual reinforcement of cytotoxicity, i.e., synergy. These results are consistent with the 
antioxidant properties of nitroxyls at low and their pro-oxidant properties at high 
concentrations. 
Data on the cytotoxicity of PNCs also reflects the antagonism of platinum and nitroxyl 
pharmacophores. Complexes of platinum (II) 2b and 30b, containing nitroxyl radicals of 
different structure, are significantly less toxic to tumor cells compared to cisplatin (Table 1). 
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Figure 12. Combination index [log (CI)] versus fraction affected (fa) of HeLa cells for combination of 4-
amino-2,2,6,6-tetramethylpiperidine-1-oxyl and cisplatin. 
Cell 
line 
IC50, µM 
Cis-
platin 
2b 30b JM216 9b 9c 10b 10c 10d 10e 10f 
HeLa 14.8 125 112 14.4 >200* 13.4 200 4.18 2.45 0.23 0.09 
H1299 66.7 >150* >150* 38.8 >200* 25.4 220 24.6 16.6 1.36 0.69 
Table 1. 50% Inhibitory concentrations for PNCs in HeLa and H1299 cells; MTT assay, 24 h of exposure. 
*Evaluation of IC50 is limited by low solubility of complexes. 
Platinum(IV)-nitroxyl complexes 9b and 10b, being structurally close to JM-216, are also 
considerably less toxic to cells compared to the latter. Elongation of axial ligands Y increases 
both lipophilicity and cytotoxicity (complexes 9c and 10c-f), which is obviously due to the 
increased accumulation of complexes in cells (Fig. 13). 
 
Figure 13. Relationship between lipophilicity (log POW) and cytotoxicity (IC50) of complexes 10b-f in 
HeLa () and H1299 () cell lines; n means the total number of carbon atoms in carboxylic residues Y. 
0 2 4
0,1
1
10
100
n
 =
1
6
n
 =
1
2
n
 =
1
0
n
 =
8
NH2N
O
Pt
H3N Cl
Cl
OY
OY
5b-f
IC
5
0
, 
M
log Pow
n
 =
4
 
 
Platinum Complexes with Bioactive Nitroxyl Radicals: Synthesis and Antitumor Properties 395 
The H1299 cells are less sensitive to platinum complexes. Unlike the HeLa cells, H1299 cells 
do not contain p53 protein because of mutations of p53 gene in both alleles (Mitsudomi et 
al., 1992). Since p53 protein plays a key role in the process of apoptosis in response to DNA 
damages (Vousden & Prives, 2009), the observed lower sensitivity of H1299 cells to 
platinum complexes compared to HeLa cells can be related to lack of p53 function. 
Our further study was focused on complex 10d since it combined high cytotoxicity with 
sufficient solubility in water. The effect of complex 10d and cisplatin on the cell cycle of 
HeLa and H1299 cells was studied (Fig. 14). According to flow cytofluorimetry data, both 
complexes cause approximately fivefold increase in the number of HeLa cells in the subG1 
fraction, thus indicating induction of cell death. Accumulation of HeLa cells in early S phase 
was also observed, which suggests that cell death is induced after cell cycle arrest during 
DNA synthesis. For H1299 cells, some increase in the S phase population and two-fold 
decrease in G2/M phases population was demonstrated, which shows cytostatic activity of 
the complexes without significant cell death. 
 
Figure 14. Cell cycle analysis of HeLa and H1299 cells treated with cisplatin and complex 10d 
(concentration IC50, 24 h). 
Cell death found in flow cytofluorimetry experiments was shown to be apoptotic. Both 
cisplatin and complex 10d cause in HeLa cells characteristic for apoptosis morphological 
changes of cell nuclei and internucleosomal cleavage of DNA leading to electrophoretic 
DNA laddering (Fig. 15a-d).  
As it was discussed above, cisplatin and its analogues form adducts with DNA that, when 
are not repaired, trigger the tumor suppressor protein p53 (Alderden et al., 2006; Kelland, 
2007; Wheate et al., 2010). Unlike cisplatin, the 10d complex does not cause increase of the 
p53 protein expression in MCF7 cells containing wild-type p53 gene (Fig. 15e). This finding 
indicates differences in the mechanism of cytotoxic action of these two complexes. 
Interestingly, on the rat glioma C6 cells, the simple nitroxyl Tempol was shown to cause 
apoptosis without elevation of p53 protein levels (Gariboldi et al., 2003). Many compounds  
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Figure 15. The mechanism of cytotoxicity of platinum complexes. a—c DAPI staining of DNA in HeLa 
cells in the control (a) and after 24 h exposure to cisplatin (CP) (b) or complex 10d (c); arrows indicate 
the fragmented nuclei of the apoptotic cells. d Agarose gel electrophoresis of HeLa cells DNA after 12 h 
and 24 h exposure to CP and complex 10d. e Immunoblotting of MCF7 cell lysates with antibody to p53 
in the control (C) and after 6 h exposure to CP and complex 10d. 
including nitroxyls (Sui at al., 2005) and platinum complexes (Gorczyca et al., 1993; 
Kalimutho et al., 2011; Roubalová et al., 2010) induce apoptosis both in cells with wild-type 
p53 gene and in p53-deficient cells. However, p53-independent apoptosis of tumor cells 
harboring wild-type p53 gene, to our knowledge, was observed for the first time. 
5. Antitumor activity of PNCs in animal experimental tumors 
Data on cytotoxicity revealed from cell culture studies and antitumor activity observed in 
animal tumor models do not correlate for platinum complexes. A striking example of this 
phenomenon is carboplatin, the known antitumor chemotherapy drug possessing negligible 
cytotoxicity in vitro. Carboplatin has been approved for clinical use because of favorable 
efficiency to toxicity ratio found in animal tumor models (Jakupec et al., 2008). 
5.1. Pt(II) complexes 
Toxicity and biological activity of Pt(II) diamino complexes depend on the structure of both 
the carrier amino ligands and the leaving groups, the latter being replaced during 
metabolism and target binding (Ho et al., 2003). The biradical complexes 1 containing two 
bulky amino ligands poorly bind to DNA in vitro (see above) and exhibit low toxicity and 
antitumor activity in vivo (Table 2). 
Complexes 2 and 3 bearing one bulky substituent are close in their properties to cisplatin. 
Their LD50 values are only 1.5 to 2.5-fold higher than that of cisplatin. They efficiently platinate 
DNA and exhibit antitumour activity comparable with cisplatin. Influence of the nitroxyl 
structure on the complex activity can be seen when comparing complexes 2b and 30b that 
differ only in the size of nitroxyl cycle. Compound 30b is both more toxic and more active 
against leukemia P388. For complexes 4, the correlation between the rate of leaving ligands  
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Complex LD50, mg·kg–1 (mM·kg–1) Single dose, mg·kg–1 ILS, % 
1b 570 (0.94) 190 106 (0) 
1c∙H2O 500 (0.74) 166 79(1) 
1d 380 (0.61) 127 76 (0) 
2b 27 (0.061) 6.8 237 (1) 
30b 15 (0.033) 3.8 292 (2) 
4b 80 (0.18) 16 189 (0) 
4c 11 (0.022) – – 
4d·2H2O 50 (0.10) 11 132 (0) 
4e 500 (0.95) 133 202 (2) 
9a 45 (0.095) 15 133 (0) 
9b 100 (0.180) 34 247 (0) 
10a∙2H2O 27 (0.052) 9 270 (4) 
10b 46 (0.080) 7.5 220 (4) 
10d 4.5 (0.007) 1.5 120 (1) 
11b 260 (0.38) 87 290 (1) 
Cisplatin 12 (0.040) 3.0 245(1) 
Table 2. Toxicity (LD50) and antileukemic (P388) activity (ILS) of PNCs. LD50 is a dose which is lethal to 
50% of healthy mice. Increase in the life span ILS = [100(T/C – 1)], where T and C the average life-time 
(days) of treated and control animals, respectively. The numbers of animals survived for more than 60 
days in the group of six animals are given in brackets. 
hydrolysis and the toxicity was established (Sen’ et al., 1996; Shugalii et al., 1998). Readily 
hydrolyzable 4c has the highest toxicity whereas 4e, the most slowly hydrolyzable 
compound among complexes 4, exhibits the lowest toxicity, but, like carboplatin, it 
possesses good antitumor activity only at high doses. Compound 4d, the structural 
analogue of oxaliplatin, is approximately 2-fold less toxic compared to the latter. The 
observed decrease in toxicity might be due to the influence of the nitroxyl group. The data 
presented demonstrate that, among Pt(II) complexes with amino nitroxyl radicals, high 
antitumor activity in vivo is characteristic for those that contain no more than one bulky 
amino ligand, platinate DNA with high efficiency, and cause moderate destabilization of 
DNA duplex (Fig. 9, Table 2). 
5.2. Pt(IV) complexes 
Toxicity of Pt(IV) complexes 9 and 10 varies in the wide range depending on the structure of 
axial ligands. Compounds 9a,b and 10a,b are 1.6 to 3-fold less toxic compared to the 
corresponding Pt (II) analogues, 2 and 3 (Table 2). As in the case of divalent complexes, the 
piperidine oxyl derivatives 10 are both more toxic and more active against leukemia P388 
than pyrrolidine oxyl derivatives 9. 
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An important feature of PNCs is found in comparative study of development of tumor 
resistance in leukemia P388 to complex 10a and cisplatin (Sen’ et al., 2003; Goncharova et al., 
2011). The development of resistance was induced by sequential inoculation of tumor cells 
from animals treated with equitoxic doses of drugs. The tumor acquired resistance (≤ 20% of 
the sensitivity of the parent tumor) to cisplatin at the 4th and to complex 10a at the 10th 
generation of tumor (Fig. 16). This data demonstrate that the resistance to complex 10a 
develops 2.5-fold slower than that to cisplatin. 
Interesting results were observed when PNCs and cisplatin were used in combination at low 
doses (1/10 to 1/20 of LD50) for leukemia P388 treatment. Individual compounds in the same 
doses caused low ILS–indices with no cured animals, but their combinations cured up to 
100% of mice (Fig. 17). 
Complexes 10a and 10b containing piperidinoxyl moiety exhibit higher antitumor activity 
compared to that of complex 9b, both as single agents and in combination with cisplatin. 
Thus, small difference in the structure of nitroxyl radicals in these PNCs has a significant 
influence on their antitumor activity in vivo.  
 
Figure 16. Development of resistance to cisplatin and complex 10a in a series of successive transplant 
generations (n). ILS0 is the increase in the life span of treated animals bearing the sensitive (parent) 
generation of leukemia P388. 
It is known that reduction potentials E1/2(>N+=O/>N─O) of nitroxyls of piperidine series are, 
on the average, approximately 0.1 V lower than that of radicals of pyrrolidine series 
(Goldstein et al., 2006; Manda et al., 2007; Sen’ & Golubev, 2009). Therefore, piperidinoxyls 
are oxidized by HO2 radical more readily (Fig. 10), and they are more efficient superoxide 
dismutase mimetics compared to pyrrolidinoxyls (Goldstein et al., 2006). At the same time, 
in vivo, pyrrolidinoxyls undergo reduction to corresponding hydroxylamines about tenfold 
slower than piperidinoxyls (Komarov et al., 1994). Along with possible differences in 
pharmacokinetics of the complexes, these features of the redox properties of nitroxyls, 
presumably, affect the biological activity of PNCs. 
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Figure 17. Synergy for the antitumor effect of cisplatin (0.6 mg/kg) combined with complexes 9b (2,3 
mg/kg), 10a (1,4 mg/kg) or 10b (5,0 mg/kg) against leukemia P388 (days of treatment 1, 3, 5, 7). 
6. Conclusion 
Recent studies (Wondrak, 2009; DeNicola et al., 2011) show that modulation of the redox 
state of cancerous cells could provide a new approach to suppression of tumor growth. 
Effects of nitroxyl radicals on the redox processes in normal cells and their cytotoxicity in 
tumor cells are documented in many examples (Gariboldi et al., 2000; Suy et al., 2005; 
Wilcox, 2010). Presumably, nitroxyls may affect the tumor cell viability through a redox-
mediated signaling, which ultimately activate apoptosis.  
On the other hand, the influence of nitroxyl radical on activity of anticancer agent, when 
they are used in combination or are covalently linked in one molecule, appears to depend on 
local concentration of radicals. At low concentrations of nitroxyls, which corresponds to 
rather low therapeutic doses of hybrid compounds, radicals are likely to impair the 
oxidative stress caused by tumor process and an anticancer agent itself. Published data 
show that in vivo the overall and/or specific toxicity may be reduced for hybrid compounds 
without significant loss of antitumor activity. On the other hand, high concentrations of 
nitroxyls, which can be implemented in combinations with anticancer agents, increase the 
intrinsic oxidative stress in tumor cells and exert a selective cytotoxic effect. 
The known active anticancer complexes like cisplatin, oxaliplatin, and satraplatin bear in 
their structure redox-inert amino ligands. We synthesized structurally close analogs, i.e., 
platinum-nitroxyl complexes, amino ligands of which hold a wide spectrum of redox 
activity and are able to modulate biological properties of the new compounds. Their 
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physicochemical properties, interaction with DNA, cytotoxicity in vitro and antitumor 
activity in vivo were studied. A limited correlation was found between the ability of new 
complexes to form adducts with DNA, thermal stability of these adducts and antitumor 
activity of the complexes. PNCs are characterized by features that distinguish them from 
platinum complexes with usual alkylamines. An antagonism of platinum and nitroxyl 
pharmacophore was observed in cell culture. As compared to cisplatin or satraplatin, 
structurally close nitroxyl derivatives are approximately 10 times less cytotoxic. This may be 
explained by a moderate inhibition of p53-dependent apoptosis due to the antioxidant 
properties of nitroxyl radicals. These in vitro findings do not correlate with in vivo data, and 
antitumor activities of some PNCs and cisplatin are approximately the same. The relatively 
slow development of resistance to PNCs and the presence of synergy for the combinations 
of PNCs and cisplatin imply the differences in the mechanism of antitumor action of 
cisplatin and PNCs. Due to antioxidant properties (Sen’ et al., 2000), nitroxyls in PNCs may 
ameliorate side effects typical for cisplatin, such as nephrotoxicity and neurotoxicity. For 
example, nitroxyl derivative of daunorubicin, ruboxyl, has virtually no cardiotoxicity that 
limits therapeutical doses of the parental compound (Emanuel & Konovalova, 1992). 
Reduced side effects, in turn, contribute to the better survival and, as a result, the higher 
efficacy of tumor chemotherapy in vivo. Our and literature data show that nitroxyls are 
promising modulators of the activity of anticancer agents and, as such, could be approved 
for clinical use. 
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